References

1. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002.

   View at: Publisher Site | Google Scholar

2. M. S. Wolfe, “The $\gamma$-secretase complex: membrane-embedded proteolytic ensemble,” Biochemistry, vol. 45, no. 26, pp. 7931–7939, 2006.

   View at: Publisher Site | Google Scholar

3. N. Takasugi, T. Tomita, I. Hayashi et al., “The role of presenilin cofactors in the $\gamma$-secratase complex,” Nature, vol. 422, no. 6930, pp. 438–441, 2003.

   View at: Publisher Site | Google Scholar

4. W. K. Taylor, M. J. LaVoie, B. L. Ostaszewski, W. Ye, M. S. Wolfe, and D. J. Selkoe, “$\gamma$-secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6382–6387, 2003.

   View at: Publisher Site | Google Scholar

5. M. Niimura, N. Isoo, N. Takasugi et al., “Aph-1 contributes to the stabilization and trafficking of the $\gamma$-secretase complex through mechanisms involving intermolecular and intramolecular interactions,” The Journal of Biological Chemistry, vol. 280, no. 13, pp. 12967–12975, 2005.

   View at: Publisher Site | Google Scholar

6. N. Isoo, C. Sato, H. Miyashita et al., “$\text{A}\beta 42$ overproduction associated with structural changes in the catalytic pore of $\gamma$-secretase: common effects of Pen-2 N-terminal elongation and fenofibrate,” The Journal of Biological Chemistry, vol. 282, no. 17, pp. 12388–12396, 2007.

   View at: Publisher Site | Google Scholar

7. S. Shah, S. F. Lee, K. Tabuchi et al., “Nicastrin functions as a $\gamma$-secretase-substrate receptor,” Cell, vol. 122, pp. 435–447, 2005.

   View at: Google Scholar

8. B. De Strooper, P. Saftig, K. Craessaerts et al., “Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein,” Nature, vol. 391, no. 6665, pp. 387–390, 1998.

   View at: Publisher Site | Google Scholar

9. B. De Strooper, W. Annaert, P. Cupers et al., “A presenilin-1-dependent $\gamma$-secretase-like protease mediates release of notch intracellular domain,” Nature, vol. 398, no. 6727, pp. 518–522, 1999.

   View at: Publisher Site | Google Scholar

10. R. Kopan and M. X. Ilagan, “Gamma-secretase: proteasome of the membrane?,” Nature Reviews Molecular Cell Biology, vol. 5, pp. 499–504, 2004.

    View at: Google Scholar

11. D. P. Lane and L. V. Crawford, “T antigen is bound to a host protein in SV40 transformed cells,” Nature, vol. 278, no. 5701, pp. 261–263, 1979.

    View at: Google Scholar

12. D. I. Linzer and A. J. Levine, “Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells,” Cell, vol. 17, no. 1, pp. 43–52, 1979.

    View at: Google Scholar

13. A. Yagi, Y. Hasegawa, H. Xiao et al., “GADD34 induces p53 phosphorylation and p21/WAF1 transcription,” Journal of Cellular Biochemistry, vol. 90, no. 6, pp. 1242–1249, 2003.

    View at: Publisher Site | Google Scholar

14. H. Xiang, Y. Kinoshita, C. M. Knudson, S. J. Korsmeyer, P. A. Schwartzkroin, and R. S. Morrison, “Bax involvement in p53-mediated neuronal cell death,” Journal of Neuroscience, vol. 18, no. 4, pp. 1363–1373, 1998.

    View at: Google Scholar

15. E. Oda, R. Ohki, H. Murasawa et al., “Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis,” Science, vol. 288, no. 5468, pp. 1053–1058, 2000.

    View at: Publisher Site | Google Scholar

16. K. Nakano and K. H. Vousden, “PUMA, a novel proapoptotic gene, is induced by p53,” Molecular Cell, vol. 7, no. 3, pp. 683–694, 2001.

    View at: Publisher Site | Google Scholar

17. Y. Kitamura, S. Shimohama, W. Kamoshima, Y. Matsuoka, Y. Nomura, and T. Taniguchi, “Changes of p53 in the brains of patients with Alzheimer's disease,” Biochemical and Biophysical Research Communications, vol. 232, no. 2, pp. 418–421, 1997.

    View at: Publisher Site | Google Scholar

18. Y. Ohyagi, H. Asahara, D.-H. Chui et al., “Intracellular $\text{A}\beta 42$ activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease,” The FASEB Journal, vol. 19, no. 2, pp. 255–257, 2005.

    View at: Publisher Site | Google Scholar

19. S. Tomita, Y. Kirino, and T. Suzuki, “Cleavage of Alzheimer's amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism,” The Journal of Biological Chemistry, vol. 273, no. 11, pp. 6277–6284, 1998.

    View at: Publisher Site | Google Scholar

20. S. J. Baker, S. Markowitz, E. R. Fearon, J. K. V. Willson, and B. Vogelstein, “Suppression of human colorectal carcinoma cell growth by wild-type p53,” Science, vol. 249, no. 4971, pp. 912–915, 1990.

    View at: Google Scholar

21. W. S. El-Deiry, S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein, “Definition of a consensus binding site for p53,” Nature Genetics, vol. 1, no. 1, pp. 45–49, 1992.

    View at: Google Scholar

22. T. Mizutani, Y. Taniguchi, T. Aoki, N. Hashimoto, and T. Honjo, “Conservation of the biochemical mechanisms of signal transduction among mammalian notch family members,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 16, pp. 9026–9031, 2001.

    View at: Publisher Site | Google Scholar

23. S. Minoguchi, Y. Taniguchi, H. Kato et al., “RBP-L, a transcription factor related to RBP-J$\kappa$,” Molecular and Cellular Biology, vol. 17, no. 5, pp. 2679–2687, 1997.

    View at: Google Scholar

24. P. Jiang, W. Du, K. Heese, and M. Wu, “The bad guy cooperates with good cop p53: bad is transcriptionally up-regulated by p53 and forms a bad/p53 complex at the mitochondria to induce apoptosis,” Molecular and Cellular Biology, vol. 26, no. 23, pp. 9071–9082, 2006.

    View at: Publisher Site | Google Scholar

25. P. L. Mellon, C. H. Clegg, L. A. Correll, and G. S. McKnight, “Regulation of transcription by cyclic AMP-dependent protein kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 13, pp. 4887–4891, 1989.

    View at: Google Scholar

26. H. F. Dovey, V. John, J. P. Anderson et al., “Functional $\gamma$-secretase inhibitors reduce $\beta$-amyloid peptide levels in brain,” Journal of Neurochemistry, vol. 76, pp. 173–181, 2001.

    View at: Google Scholar

27. Y.-M. Li, M. Xu, M.-T. Lai et al., “Photoactivated $\gamma$-secretase inhibitors directed to the active site covalently label presenilin 1,” Nature, vol. 405, no. 6787, pp. 689–694, 2000.

    View at: Publisher Site | Google Scholar

28. T. Sekiya, M. Fushimi, H. Hori, S. Hirohashi, S. Nishimura, and T. Sugimura, “Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 15 I, pp. 4771–4775, 1984.

    View at: Google Scholar

29. T. Hiwasa, M. Nakata, M. Nakata et al., “Regulation of transformed state by calpastatin via PKC$\epsilon$ in NIH3T3 mouse fibroblasts,” Biochemical and Biophysical Research Communications, vol. 290, no. 1, pp. 510–517, 2002.

    View at: Publisher Site | Google Scholar

30. T.-L. Liu, H. Shimada, T. Ochiai et al., “Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-$\kappa$B p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism,” Apoptosis, vol. 11, no. 6, pp. 1025–1037, 2006.

    View at: Publisher Site | Google Scholar

31. T. Hiwasa, Y. Arase, K. Kikuno et al., “Increase in ultraviolet sensitivity by overexpression of calpastatin in ultraviolet-resistant ${\text{UV}}^{\text{r}}$-1 cells derived from ultraviolet-sensitive human RSa cells,” Cell Death and Differentiation, vol. 7, no. 6, pp. 531–537, 2000.

    View at: Google Scholar

32. G. Yu, M. Nishimura, S. Arawaka et al., “Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and $\beta$-APP processing,” Nature, vol. 407, pp. 48–54, 2000.

    View at: Google Scholar

33. T. Hiwasa, H. Shimada, T. Sakaida et al., “Drug-sensitivity pattern analysis for study of functional relationship between gene products,” FEBS Letters, vol. 552, no. 2-3, pp. 177–183, 2003.

    View at: Publisher Site | Google Scholar

34. C. Alves da Costa, C. Sunyach, R. Pardossi-Piquard et al., “Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease,” The Journal of Neuroscience, vol. 26, no. 23, pp. 6377–6385, 2006.

    View at: Publisher Site | Google Scholar

35. J. Dunys, T. Kawarai, and J. Sevalle, “p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the $\gamma$-secretase complex but is independent of its activity,” The Journal of Biological Chemistry, vol. 282, no. 14, pp. 10516–10525, 2007.

    View at: Publisher Site | Google Scholar

36. W. A. Campbell, H. Yang, H. Zetterberg et al., “Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss,” Journal of Neurochemistry, vol. 96, no. 5, pp. 1423–1440, 2006.

    View at: Publisher Site | Google Scholar

37. R. Pardossi-Piquard, J. Dunys, E. Giaime et al., “P53-dependent control of cell death by nicastrin: lack of requirement for presenilin-dependent $\gamma$-secretase complex,” Journal of Neurochemistry, vol. 109, no. 1, pp. 225–237, 2009.

    View at: Publisher Site | Google Scholar

38. M. E. Boulton, J. Cai, and M. B. Grant, “$\gamma$-secretase: a multifaceted regulator of angiogenesis,” Journal of Cellular and Molecular Medicine, vol. 12, no. 3, pp. 781–795, 2008.

    View at: Publisher Site | Google Scholar

39. P. Marambaud and N. K. Robakis, “Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation,” Genes, Brain and Behavior, vol. 4, no. 3, pp. 134–146, 2005.

    View at: Publisher Site | Google Scholar

40. S. H. Kim, A. C. Nairn, N. Cairns, and G. Lubec, “Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease,” Journal of Neural Transmission. Supplement, no. 61, pp. 263–272, 2001.

    View at: Google Scholar

41. F. G. De Felice, A. P. Wasilewska-Sampaio, A. C. A. P. Barbosa, F. C. A. Gomes, W. L. Klein, and S. T. Ferreira, “Cyclic AMP enhancers and $\text{A}\beta$ oligomerization blockers as potential therapeutic agents in Alzheimer's disease,” Current Alzheimer Research, vol. 4, no. 3, pp. 263–271, 2007.

    View at: Publisher Site | Google Scholar